← Back to Search

Radiation Therapy

SABR for Metastatic Cancer

N/A
Recruiting
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All sites of disease can be safely treated on a preliminary radiation plan
Age 18 or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time from randomization to death from any cause, patients followed for 5 years
Awards & highlights

Study Summary

This trial is testing a new cancer treatment called SABR to see if it's better than the current standard of care. It will involve patients with cancer that has spread to multiple parts of their body.

Who is the study for?
This trial is for adults with cancer that has spread to many places in the body, who can safely receive radiation therapy. They should not be planning any systemic treatments like chemotherapy for 3 months and must have a life expectancy of at least 6 months. Pregnant women or those with serious health issues related to radiotherapy are excluded.Check my eligibility
What is being tested?
The ARREST-2 trial compares standard cancer care (Arm 1) with Stereotactic Ablative Radiotherapy (SABR) treatment (Arm 2). It aims to see if SABR improves survival, slows disease progression, enhances quality of life, and assesses its safety.See study design
What are the potential side effects?
Potential side effects from SABR may include skin reactions, fatigue, inflammation of treated organs depending on where the radiation is targeted (like lungs or liver), and other typical risks associated with radiation therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
All my cancer areas can be safely targeted with radiation.
Select...
I am 18 years old or older.
Select...
I am able to get out of my bed or chair and move around.
Select...
My cancer has spread, and this was confirmed by tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time from randomization to death from any cause, patients followed for 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and time from randomization to death from any cause, patients followed for 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival
Secondary outcome measures
Progression-free survival
Quality of life- An individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
Toxicity of Ablative Radiotherapy

Trial Design

2Treatment groups
Active Control
Group I: SABRActive Control1 Intervention
SABR to all tumors 6Gy x 5 over 3 weeks
Group II: Standard of CareActive Control1 Intervention
Standard or care palliative radiotherapy (includes the option for no treatment)

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
655 Previous Clinical Trials
413,201 Total Patients Enrolled

Media Library

SABR (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05508464 — N/A
Cancer Research Study Groups: SABR, Standard of Care
Cancer Clinical Trial 2023: SABR Highlights & Side Effects. Trial Name: NCT05508464 — N/A
SABR (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05508464 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people currently being recruited for this trial?

"The clinicaltrials.gov website reveals that this study is not currently recruiting patients. Although the trial was first posted on 2023-01-01, the most recent update was on 2022-08-17. There are 756 other trials that are actively recruiting patients."

Answered by AI
~92 spots leftby Jan 2026